Shire has applied to the FDA for dry eye treatment approval. This will be a major headwind for Eleven. The allergic conjunctivitis angle would still be a major plus.
Yep. That's how I see it. The other possibilities are that RHBBY decides to ok the 7.7M is not exactly what we wanted but give or take a another 1M we're ok. Or, they go hostile directly to the shareholders to buy the company out.
As well as the domestic Pharm. will be contracting FMI for target therapies. The downside is minimal as you pointed out in an earlier post.
Hello OMD, I'm holding options for 2/20, well below the tender price. Is it your opinion that the long-term share price will be greater than the tender. In other word is there life beyond Roche?